Reasons to invest in GSK - a global healthcare company enabling people to do more, feel better and live longer.
Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.
No. 1 prescribed allergy treatment ingredient1 to be available OTC
GSK announced today that it has submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S.
GSK delivers Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis (both CER). Q2 dividend 19p (+6%).